SEC Comment Letter 0000000000-24-005541 to NeuroSense Therapeutics Ltd. (NRSN, NRSNW) (CIK 0001875091) (NRSN)
NeuroSense Therapeutics Ltd. (NRSN, NRSNW) (CIK 0001875091)
Date: May 14, 2024 · CIK: 0001875091 · Accession: 0000000000-24-005541
AI Filing Summary & Sentiment
File numbers found in text: 333-279324
Letter
United States securities and exchange commission logo May 14, 2024 Alon Ben-Noon Chief Executive Officer NeuroSense Therapeutics Ltd. 11 HaMenofim Street, Building B Herzliya 4672562 Israel Re:NeuroSense Therapeutics Ltd. Registration Statement on Form F-1 Filed May 10, 2024 File No. 333-279324 Dear Alon Ben-Noon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary Emmanuel, Esq.
Show Raw Text
United States securities and exchange commission logo
May 14, 2024
Alon Ben-Noon
Chief Executive Officer
NeuroSense Therapeutics Ltd.
11 HaMenofim Street, Building B
Herzliya 4672562 Israel
Re:NeuroSense Therapeutics Ltd.
Registration Statement on Form F-1
Filed May 10, 2024
File No. 333-279324
Dear Alon Ben-Noon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Gary Emmanuel, Esq.